Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

1.06
-0.1650-13.52%
Volume:809.55K
Turnover:894.51K
Market Cap:23.91M
PE:-0.08
High:1.20
Open:1.19
Low:1.05
Close:1.22
52wk High:10.99
52wk Low:1.05
Shares:22.66M
Float Shares:16.01M
Volume Ratio:0.80
T/O Rate:5.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.07
PE(LYR):-0.06

Loading ...

Mar 10, 2023

Major Issues Report

8-K - Current report
Feb 17, 2023

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Feb 17, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 15, 2023

Major Issues Report

8-K - Current report
Feb 15, 2023

Major Issues Report

8-K - Current report
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2023

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jan 09, 2023

Major Issues Report

8-K - Current report
Dec 29, 2022

Correspondence

CORRESP [Cover] - Correspondence
Dec 14, 2022

Major Issues Report

8-K - Current report
Dec 08, 2022

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Dec 05, 2022

Major Issues Report

8-K - Current report
Dec 02, 2022

Major Issues Report

8-K - Current report
Nov 03, 2022

Major Issues Report

8-K - Current report
Nov 03, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 04, 2022

Major Issues Report

8-K - Current report
Aug 04, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]